FDAnews
www.fdanews.com/articles/202636-report-says-almost-3500-gene-cell-and-rna-therapies-in-drugmaker-pipelines

Report Says Almost 3,500 Gene, Cell and RNA Therapies in Drugmaker Pipelines

May 6, 2021

The number of gene, cell and RNA therapies continues to grow rapidly with almost 3,500 treatments in either the preclinical or clinical testing phases, a new report says.

Cancer drugs still lead research and development, with nearly 1,200 therapies in development for the first quarter of 2021, according to the report. Next in line after oncology are treatments for neurological disorders, with 35 drugs in the pipeline from the preclinical to preregistration stages.

Gene therapies, including genetically modified CAR-T cell therapies, account for 53 percent of all gene, cell and RNA therapies being developed, while nongenetically modified cell therapies account for 27 percent and RNA therapies make up 20 percent of these therapies in development, the American Society of Gene & Cell Therapy says in Gene, Cell, & RNA Therapy Landscape, a report published in collaboration with Informa Pharma Intelligence.

View today's stories